Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

This is an open-label (participants and researchers are aware about the treatment
participants are receiving), multi-center (when more than 1 hospital or medical school team
work on a medical research study), drug-drug interaction (DDI) study of ibrutinib with the
moderate and the strong CYP3A inhibitors (erythromycin and voriconazole respectively) in
participants with B-cell malignancies (including Chronic Lymphocytic Leukemia /Small
Lymphocytic Lymphoma [CLL/SLL], Follicular Lymphoma [FL], Marginal Zone Lymphoma [MZL],
Waldenstrom's Macroglobulinemia [WM] or Mantle Cell Lymphoma [MCL]). The study will consist
of a Screening Phase (28 days), a Treatment Phase (consisting of six 28-days cycles), and an
End-of-Treatment (EoT) Visit (within 30 days after the last dose of study drug). The study
will consist of 2 Parts. In Part 1, extent of the DDI between ibrutinib at dose level of 140
milligram (mg) and CYP3A inhibitors will be assessed. After completion of Part 1 of the
study, an interim analysis of all available PK and safety data will be conducted and Part 2
will only be performed if the observed drug interaction is less than anticipated based on
current information. In Part 2, safety and PK of ibrutinib at dose level of 560 mg
administered with CYP3A inhibitors will be assessed. Participants who continue to derive
clinical benefit from ibrutinib treatment at the end of this study, and who are eligible to
continue in the PCI-32765CAN3001 study (NCT01804686) will end their participation in this
trial, have an EoT visit completed, and will continue receiving ibrutinib as a part of the
PCI-32765CAN3001 protocol. Participants' safety will be monitored throughout the study.

Inclusion Criteria:

- Histologically or cytologically confirmed Chronic Lymphocytic Leukemia /Small
Lymphocytic Lymphoma (CLL/SLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma
(MCL), Follicular Lymphoma (FL), or Waldenstrom's Macroglobulinemia (WM)

- Relapsed or refractory disease after at least 1 prior line of systemic therapy
(participants with FL or MZL must have failed anti-CD20 monoclonal antibody
containing chemotherapy regimen)

- Eastern Cooperative Oncology Group Performance Status score of 0 or 1

- Hematology values within the following limits: a) Absolute neutrophil count (ANC)
greater than and equal to (>=) 1.0*10^9 per liter (L); b) Platelets >=50*10^9/L
without transfusion support within 7 days; c) Hemoglobin >=8 gram per deciliter
(g/dL) without transfusion support within 7 days; d) Prothrombin time /International
normalized ratio (PT/INR) less than equal to (<=) 1.5*Upper Limit of Normal (ULN) and
activated partial thromboplastin time (aPTT) <=1.5*ULN

- Biochemical values within the following limits: a) Alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) <=3.0*ULN; b) Total bilirubin <=1.5*ULN (unless due
to Gilbert's syndrome); c) Serum creatinine <=1.5*ULN or a calculated creatinine
clearance of >=50 milliliter per minute per 1.73 square meter

Exclusion Criteria:

- Major surgery within 4 weeks of the first dose of ibrutinib

- Diagnosed or treated for malignancy other than the indication under study except for:
a) Adequately treated non-melanoma skin cancer or lentigo maligna, curatively treated
in-situ cancer without evidence of disease; b) Malignancy treated with curative
intent and with no known active disease present for >=3 years before the first dose
of ibrutinib

- History of stroke or intracranial hemorrhage within 6 months prior to the first dose
of ibrutinib

- History of galactose intolerance

- Requires anticoagulation with warfarin or equivalent vitamin K antagonists (for
example, phenprocoumon)